Exact Sciences (EXAS) Earnings: 2Q Revenue Surpasses Estimates with Significant Loss Reduction

Exact Sciences on Smartkarma

Analysts on Smartkarma, like Baptista Research, are optimistic about Exact Sciences‘ future, particularly with the launch of Cologuard Plus. According to Baptista Research‘s report titled “Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm,” Exact Sciences‘ first quarter of 2025 showed strong financial results, including an 11% increase in total revenue to $707 million. The growth was mainly driven by the Screening segment, which saw revenue rise by 14% to $540 million, propelled by successful rescreen initiatives, improved commercial strategies, and the Cologuard Plus rollout.

In another report by Baptista Research titled “Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?,” they highlighted Exact Sciences‘ positive momentum in the fourth quarter of 2024. The company achieved core revenue growth of 11% to $2.75 billion for the full year, expanded adjusted EBITDA by nearly 48%, doubled free cash flow, and ended the year with $1.04 billion in cash and securities. Analysts are keeping a bullish outlook on Exact Sciences, anticipating further growth and market capture with their innovative product pipeline.

A look at Exact Sciences Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Exact Sciences Corp. has a mixed outlook based on the Smartkarma Smart Scores analysis. While the company scores well in terms of momentum, indicating strong recent performance, it falls short in areas like dividend and resilience. With a focus on developing a non-invasive molecular screening test for colorectal cancer, Exact Sciences faces challenges in its dividend and resilience scores. However, the company shows promise in terms of growth potential and overall value, suggesting a positive trajectory in the long term.

In summary, Exact Sciences Corp. operates in the healthcare sector, specializing in the development and commercialization of a non-invasive molecular screening test for colorectal cancer. Despite facing some challenges in certain Smart Scores categories, the company’s focus on early detection and prevention of colorectal cancer positions it well for potential growth and value creation in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma